Amidst an Avalanche of Evidence, It’s Time to Stop PBM-Driven Drug Price Manipulation
In a recent opinion piece for the DC Journal, several industry experts weighed in on the consensus stance that lawmakers need to stop drug price manipulation driven by pharmacy benefit managers (PBMs). Authors for this article included Mark Blum, managing...